Earlier and more widespread adoption of advanced therapies—including biologics and small molecules—has not meaningfully altered long-term outcomes in Crohn’s disease at a population level, according to 10-year data from the pan-European Epi-IBD cohort.
Despite marked regional differences in treatment intensity and timing, patients in Western and Eastern Europe experienced nearly identical rates of surgery, disease progression, and hospitalization over a decade of follow-up.Published in Clinical Gastroenterology and Hepatology, the analysis draws on one of the most rigorous contemporary IBD datasets available. The Epi-IBD cohort prospectively followed unselected, newly diagnosed Crohn’s disease patients across 22 centers in Europe, using standardized data collection to capture real-world disease trajectories across different healthcare systems and treatment philosophies.
Keep Reading
Add A Comment